Phantom Neuro
Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface using proprietary AI and subcutaneous sensors to decode muscle signals for intuitive prosthetic limb control. The Austin-based company, founded in 2020, targets amputees and is pursuing FDA approval.
- Company typePrivate
- Founded2020
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Phantom Neuro does
Phantom Neuro is a clinical-stage neurotechnology company developing the Phantom X, a minimally invasive muscle-machine interface (MMI) that captures electrical signals from residual limb muscles through a subcutaneous implantable sensor and uses proprietary AI algorithms to decode movement intent in real-time for intuitive control of prosthetic limbs and robotic systems. Founded in 2020 by Connor Glass and headquartered in Austin, Texas, the platform has demonstrated 94% accuracy across 11 distinct hand and wrist movements in the ASCENT non-invasive validation study, with 10 minutes of calibration restoring up to 85% of hand and wrist functionality. The system is designed as a simple outpatient procedure—accessible to over 70,000 US practitioners—positioning it as a less invasive alternative to brain-computer interfaces for amputees.
The company is pursuing FDA regulatory approval and received both Breakthrough Device Designation and TAP Acceptance in 2025. Its first-in-human CYBORG Early Feasibility Study, approved in Australia in April 2026, will enroll up to 10 upper limb amputee participants over approximately 20 weeks at Cabrini Health in Melbourne, with prosthetic care provided by ProMotion Prosthetics and Enable Rehab. The Australian study is structured to support a future US FDA IDE submission and pivotal trial. Beyond prosthetics, Phantom Neuro is positioning its in-vivo movement data capture as a training asset for humanoid robotics and human-machine collaboration applications, with an active partnership with DARPA covering defense and exoskeleton use cases.
Phantom Neuro's business model is anchored on medical device hardware sales of the Phantom X system, with a secondary optionality around licensing its sensing platform and movement data to robotics companies. The company operates an enterprise medical device commercialization pathway—maintaining a community patient registry (registry.phantomneuro.com) for clinical trial recruitment, engaging in scientific publications, and leveraging its strategic partnership with Ottobock for distribution. Ottobock led the $19M Series A in April 2025 and holds a board seat, contributing global prosthetics commercialization expertise. The company has raised approximately $28M in total disclosed funding across seed, Series A, and non-dilutive DARPA support, with no commercial revenue to date.
Phantom Neuro firmographics
Firmographics- Name
- Phantom Neuro
- Legal name
- Phantom Neuro Inc.
- Website
- https://phantomneuro.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface using proprietary AI and subcutaneous sensors to decode muscle signals for intuitive prosthetic limb control. The Austin-based company, founded in 2020, targets amputees and is pursuing FDA approval.
- Ownership category
- akta.pro rank
Phantom Neuro industry classification
Industry- Product category
- Implantable Neuroprosthetics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Robot Hardware, Actuators & Components (sensors, grippers, motors) (HDAAAIAL)
Keywords
Where Phantom Neuro is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Phantom Neuro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Phantom Neuro will generate revenue through the sale of its Phantom X implantable neural interface system and associated prosthetic devices. The company is pursuing FDA regulatory approval to commercialize its technology for prosthetic limb control, targeting the medical device market for amputees and individuals with limb differences.
- Technology Licensing: The company is exploring licensing its sensing platforms and movement data collection technology to robotics companies for human-robot collaboration applications.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Phantom Neuro product offering
Product offeringCore offering
Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface (MMI) system for prosthetic limb control. The system uses a subcutaneous implantable sensor that captures electrical signals directly from residual limb muscles and proprietary AI algorithms to decode movement intentions in real-time, enabling intuitive control of prosthetic hands, wrists, and robotic systems. Achieved 94% accuracy decoding 11 distinct hand and wrist movements in clinical studies.
Product overview
Phantom Neuro offers a unified product platform anchored by the Phantom X muscle-machine interface system, designed to provide intuitive prosthetic limb control for amputees through an implantable sensor and AI-powered signal processing. The system achieved 94% accuracy in the ASCENT study and is undergoing first-in-human clinical evaluation through the CYBORG study in Australia. Supporting the core technology is a patient community registry platform for clinical trial recruitment and engagement. The company positions its technology for applications beyond prosthetics, including robotics and human augmentation, with a focus on defense and security markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Phantom X A muscle-machine interface (MMI) system consisting of a minimally invasive subcutaneous implantable sensor that captures electrical signals from residual limb muscles and proprietary AI-powered signal processing that decodes movement intent in real time. Provides amputees and individuals with limb difference with intuitive, multi-degree-of-freedom control of prosthetic hands, wrists, and robotic systems. For healthcare providers, prosthetists, and amputees.
- Phantom Neuro Community Registry A patient registry and community platform that connects individuals with limb loss and mobility challenges to clinical trial opportunities, providing updates on technology, research advancements, and patient stories. For amputees, caregivers, healthcare providers, and clinical research partners.
Quantifiable outcome
- 94% accuracy in decoding real-time gestures across 11 distinct hand and wrist movements
- +3 more outcomes
Companies that use Phantom Neuro
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Phantom Neuro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Phantom Neuro partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Cabrini HealthcoreClinical study site for CYBORG first-in-human Early Feasibility Study in Melbourne, Australia, performing surgical procedures for the Phantom X system implantation.
- ProMotion ProstheticscoreClinical partner providing prosthetic care for participants in the CYBORG first-in-human study in Melbourne, Australia.
- Enable RehabcoreClinical partner providing rehabilitation services for participants in the CYBORG first-in-human study in Melbourne, Australia.
Scale indicators15 records
Recent moves5 records
Expansion highlights6 records
Phantom Neuro competitors and assessment
Company assessmentBroad incumbents
- Ottobock: Global prosthetics incumbent and Phantom Neuro's Series A lead/board partner; broader portfolio of prosthetics and exoskeletons that could ultimately bundle or compete with Phantom Neuro's interface.
- Neuralink: High-profile implantable brain-computer interface company pursuing motor control and broader cognitive applications; competes for clinical, regulatory, and capital attention in the implantable neuro interface category.
- Össur: Established global prosthetics and exoskeleton manufacturer with broad product lines; a key channel partner candidate and competitive incumbent in the amputee device market Phantom Neuro addresses.
Direct peers
- CTRL Labs (Meta / Reality Labs): Acquired by Meta, CTRL Labs developed wrist-worn EMG-based gesture decoding — the same muscle-signal decoding category Phantom Neuro pursues, though non-invasive. Phantom Neuro advisor Josh Duyan is former CSO.
- Blackrock Neurotech: Implantable neural interface company with motor-prosthetic applications; already an investor in Phantom Neuro, indicating direct category overlap in implantable neuroprosthetic control.
- Synchron: Direct neural interface competitor developing implanted brain-computer interfaces for motor control. Closely comparable in stage, regulatory pathway, and investor overlap (Synchron's founder/CEO Tom Oxley is a Phantom Neuro advisor).
- Coapt: Specialist in pattern-recognition control systems for myoelectric prosthetic limbs; directly competes for the same amputee customer segment using non-invasive EMG rather than an implantable interface.
Emerging players
- BrainCo: BCI/neurotechnology company developing non-invasive wearable EMG/EEG products; an emerging player with adjacent neural-interface technology targeting similar rehabilitation and human-performance use cases.
- Myomo: Commercial-stage myoelectric orthotic device company; adjacent to Phantom Neuro's rehab/restoration focus, addressing upper-limb mobility impairment via EMG-driven wearable robotics.
- Infinite Biomedical Technologies: Develops pattern-recognition and EMG-based prosthetic control technologies; comparable in targeting the upper-limb amputee segment with myoelectric signal decoding, though non-invasive.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Phantom Neuro social profiles
Digital presencePhantom Neuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phantom Neuro leadership team
Management profileNumber of profiles
Profiles18 records
Phantom Neuro funding detail
Funding detailFunding overview
Funding rounds5 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phantom Neuro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phantom Neuro
What does Phantom Neuro do?
Phantom Neuro develops the Phantom X, a minimally invasive muscle-machine interface (MMI) system for prosthetic limb control. The system uses a subcutaneous implantable sensor that captures electrical signals directly from residual limb muscles and proprietary AI algorithms to decode movement intentions in real-time, enabling intuitive control of prosthetic hands, wrists, and robotic systems. Achieved 94% accuracy decoding 11 distinct hand and wrist movements in clinical studies.
Is Phantom Neuro a public or private company?
Phantom Neuro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phantom Neuro founded?
Phantom Neuro was founded in 2020. It employs 11 to 50 people.
Where is Phantom Neuro based?
Phantom Neuro is headquartered in Austin, United States, in the North America region.
How does Phantom Neuro make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are technology Licensing.
Who are Phantom Neuro's main competitors?
Broad incumbents on record are Ottobock, Neuralink and Össur. Direct peers are CTRL Labs (Meta / Reality Labs), Blackrock Neurotech, Synchron and Coapt. Emerging players are BrainCo, Myomo and Infinite Biomedical Technologies.
Does Phantom Neuro have an API?
No public API is recorded for Phantom Neuro.
What industry is Phantom Neuro in?
Phantom Neuro's product category is Implantable Neuroprosthetics. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HSADAIAC, Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS). Its NAICS code is 334510.